By Dr Christine Schuberth-Wagner (CatalYm)2024-04-03T09:39:41
Dr Christine Schuberth-Wagner serves as Chief Scientific Officer at CatalYm. She joined the company in November 2018 with more than 10 years of experience in drug discovery and non-clinical development of immunomodulatory drugs in the immuno-oncology space. She has established a track record as a successful leader and entrepreneur ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2025-08-28T10:00:24Z
2024-01-26T13:22:42
Sponsored by bit.bio
2024-03-08T10:00:25
Sponsored by Molecular Devices
2023-07-04T10:05:58
Sponsored by Revvity
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2023-02-16T14:53:10
Sponsored by Cell Signaling Technology
2023-02-02T11:05:15
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud